


FORM PTO-139 (REV. 01-2003) <b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</b>		US DEPARTMENT OF COMMERCE PATENT & TRADEMARK OFFICE  ATTORNEY'S DOCKET NUMBER 128125
INTERNATIONAL APPLICATION NO. PCT/FR2004/050748		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/582,674
INTERNATIONAL FILING DATE December 22, 2004		PRIORITY DATE CLAIMED December 23, 2003
TITLE OF INVENTION ISOLATED CYTOTOXIC FACTOR ASSOCIATED WITH MULTIPLE SCLEROSIS AND METHOD OF DETECTING SAID CYTOTOXIC FACTOR		
APPLICANT(S) FOR DO/EO/US Herve PERRON; Anne EVENO-NOBILE; Jacques PORTOUKALIAN; Nicole BATTAIL-POIROT		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> <li>1. <input type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>2. <input checked="" type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</li> <li>4. <input type="checkbox"/> The US has been elected (Article 31).</li> <li>5. <input type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))             <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> has been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2))             <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto.</li> <li>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</li> <li>c. <input type="checkbox"/> The International Application was filed in English.</li> </ol> </li> <li>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))             <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> have been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</li> <li>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li> </ol>		
<b>Items 11 to 20 below concern document(s) or information included:</b>		
<ol style="list-style-type: none"> <li>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li>12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li>13. <input type="checkbox"/> A preliminary amendment.</li> <li>14. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76.</li> <li>15. <input type="checkbox"/> A substitute specification.</li> <li>16. <input type="checkbox"/> A power of attorney and/or change of address letter.</li> <li>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.</li> <li>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</li> <li>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</li> <li>20. <input type="checkbox"/> Other items or information:</li> </ol>		

U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5) 10/582,674	INTERNATIONAL APPLICATION NO. PCT/FR2004/050748	ATTORNEY'S DOCKET NUMBER 128125		
21. <input checked="" type="checkbox"/> The following fees are submitted:		<b>CALCULATIONS</b> PTO USE ONLY		
<b>BASIC NATIONAL FEE (37 CFR 1.492(a)):</b> ..... \$ 300.00		\$		
<b>SEARCH FEE (37 CFR 1.492(b)(1)-(3)):</b>		\$		
International preliminary examination report or written opinion prepared by the USPTO as IPEA or ISA and favorable as to novelty, inventive step, and industrial applicability for all claims presented in the application entering the national phase ..... \$ 0.00				
International search fee (37 CFR 1.445(a)(2)) paid to USPTO as ISA ..... \$ 100.00				
International search report provided to USPTO no later than the time at which the search fee is paid ..... \$ 400.00				
All situations not provided for above ..... \$ 500.00				
<b>EXAMINATION FEE (37 CFR 1.492(c)(1)-(2)):</b>		\$		
International preliminary examination report or written opinion prepared by the USPTO as IPEA or ISA and favorable as to novelty, inventive step, and industrial applicability for all claims presented in the application entering the national phase ..... \$ 0.00				
All situations not provided for above ..... \$ 200.00				
Surcharge of <b>\$130.00</b> for furnishing the search fee, the examination fee or the oath or declaration after the date of commencement of the national phase (37 CFR 1.492(h)).		\$		
APPLICATION SIZE FEE Total pages - 100 =	÷ 50	= +	x 250 =	\$
round up to next integer				
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$
TOTAL CLAIMS	- 20	=	x 50.00 =	\$
INDEPENDENT CLAIMS	- 3	=	x 200.00 =	\$
MULTIPLE DEPENDENT CLAIM(S)(if applicable)			+ 360.00 =	\$
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by $\frac{1}{2}$ .				\$
<b>SUBTOTAL =</b>				\$
Processing fee of <b>\$130.00</b> for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).				\$
<b>TOTAL NATIONAL FEE =</b>				\$
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property +				\$40.00
<b>TOTAL FEES ENCLOSED =</b>				\$40.00
				Amount to be refunded: \$
				charged: \$
a. <input checked="" type="checkbox"/> Check No. 183730 in the amount of \$40.00 to cover the above fees is enclosed.				
b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed.				
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 15-0461. A duplicate copy of this sheet is enclosed.				
d. <input type="checkbox"/> Fees are to be charged to a credit card. <b>WARNING:</b> Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.				
<b>NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>				
SEND ALL CORRESPONDENCE TO: OLIFF & BERRIDGE, PLC Customer Number: 25944				
 NAMES: William P. Berridge REGISTRATION NUMBER: 30,024				
NAME: Kristin K. Vidovich REGISTRATION NUMBER: 41,448				
Date <u>September 1, 2006</u>				

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Herve PERRON et al.

Group Art Unit:

Application No.: 10/582,674

Examiner:

Filed: June 12, 2006

Docket No.: 128125

For: ISOLATED CYTOTOXIC FACTOR ASSOCIATED WITH MULTIPLE SCLEROSIS AND  
METHOD OF DETECTING SAID CYTOTOXIC FACTOR

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- 1. This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date of this non-CPA application, OR (b) before the mailing date of a first Office Action on the merits in the present application. No certification or fee is required.
- 2. One or more reference cited herein was cited in the International Search Report. An English language version of the International Search Report is attached for the Examiner's information. See References 1-4.
- 3. In accordance with 37 CFR §1.98(a)(2)(ii), copies of any U.S. patents and patent application publications are not attached.
- 4. An English language Abstract of one or more non-English language reference is attached hereto. See Reference 2.

5. Reference 1 is an English Language version of WO 01/05422 on the International Search Report.

Respectfully submitted,



William P. Berridge  
Registration No. 30,024

Kristin K. Vidovich  
Registration No. 41,448

WPB:KKV/smo

Date: September 1, 2006

**OLIFF & BERRIDGE, PLC**  
**P.O. Box 19928**  
**Alexandria, Virginia 22320**  
**Telephone: (703) 836-6400**

DEPOSIT ACCOUNT USE  
AUTHORIZATION  
Please grant any extension  
necessary for entry;  
Charge any fee due to our  
Deposit Account No. 15-0461

Form PTO-1449 (REV. 1/06)			US Dept. of Commerce PATENT & TRADEMARK OFFICE <b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)		ATTY DOCKET NO. 128125		APPLICATION NO. 10/582,674	
					APPLICANT(S) Herve PERRON et al.			
					FILING DATE June 12, 2006			
<b>U.S. PATENT DOCUMENTS</b>								
Examiner Initials	Cite No.	Document Number	Date	Name				
	1.	7,081,345 B1	07/25/2006	Roecklin et al.				
<b>FOREIGN PATENT DOCUMENTS</b>								
Examiner Initials	Cite No.	Document Number	Date	Country		With English Abstract	With English Translation	
<b>OTHER DOCUMENTS</b>								
Examiner Initials	Cite No.	(Including Author, Title, Date, Pertinent Pages, etc.)						
	2.	Rieger, F. et al., "Un facteur gliotoxique et la sclérose en plaques - Gliotoxicity in multiple sclerosis," <i>C. R. Acad. Paris, Sciences de la vie/Life sciences</i> 319: 343-350 (1996)						
	3.	Malcus-Vocanson, C. et al., "Glial toxicity in urine and multiple sclerosis," <i>Multiple Sclerosis</i> 7: 383-388 (2001)						
	4.	Ménard, A. et al., "A gliotoxic factor and multiple sclerosis," <i>Journal of Neurological Sciences</i> 154: 209-221 (1998)						
	5.	Malcus-Vocanson, C. et al., "A urinary marker for multiple sclerosis," <i>Lancet</i> 351: 1330 (May 1998)						
	6.	Ménard, A. et al., "Gliotoxicity, reverse transcriptase activity and retroviral RNA in monocyte/macrophage culture supernatants from patients with multiple sclerosis," <i>FEBS Letters</i> 413: 477-485 (1997)						
	7.	Ménard, A. et al., "Detection of a gliotoxic activity in the cerebrospinal fluid from multiple sclerosis patients," <i>Neuroscience Letters</i> 245: 49-52 (1998)						
	8.	Benjelloun, N. et al., "DNA Fragmentation in Glial Cells in a Cerebral Biopsy from a Multiple Sclerosis Patient," <i>Cellular and Molecular Biology</i> 44(4): 579-583 (1998)						
	9.	Blazar, B.R. et al., "Anti-CD3εF(ab') <sub>2</sub> Fragments Inhibit T Cell Expansion in Vivo During Graft-Versus-Host Disease or the Primary Immune Response to Nominal Antigen," <i>Journal of Immunology</i> 159: 5821-5833 (1997)						
	10.	Bird, R.E. et al., "Single-Chain Antigen-Binding Proteins," <i>Science</i> 242: 423-426 (October 1988)						
EXAMINER							DATE CONSIDERED	
Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

Form PTO-1449 (REV. 1/06)		US Dept. of Commerce PATENT & TRADEMARK OFFICE		ATTY DOCKET NO. 128125	APPLICATION NO. 10/582,674
INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		APPLICANT(S) Herve PERRON et al.			
		FILING DATE June 12, 2006		GROUP	
U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number	Date	Name	
FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number	Date	Country	With English Abstract
OTHER DOCUMENTS					
Examiner Initials	Cite No.	(Including Author, Title, Date, Pertinent Pages, etc.)			
	11.	Arakawa, F. et al., "Cloning and Sequencing of the V <sub>H</sub> and V <sub>K</sub> Genes of an Anti-CD3 Monoclonal Antibody, and Construction of a Mouse/Human Chimeric Antibody," <i>Journal of Biochemistry</i> 120: 657-662 (1996)			
	12.	Chaudhary, V.K. et al., "A recombinant immunotoxin consisting of two antibody variable domains fused to <i>Pseudomonas</i> extoxin," <i>Nature</i> 339: 394-397 (June 1989)			
	13.	Jones, P.T. et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," <i>Nature</i> 321: 522-525 (May 1986)			
	14.	Riechmann, L. et al., "Reshaping human antibodies for therapy," <i>Nature</i> 332: 323-327 (March, 1988)			
	15.	Galiana, E. et al., "Establishment of Permanent Astroglial Cell Lines, Able to Differentiate in Vitro, From Transgenic Mice Carrying the Polyoma Virus Large T Gene: An Alternative Approach to Brain Cell Immortalization," <i>Journal of Neuroscience Research</i> 26: 269-277 (1990)			
EXAMINER				DATE CONSIDERED	
Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					